Alterity Therapeutics Limited - American Depositary Shares (ATHE)
5.1600
+0.2600 (5.31%)
NASDAQ · Last Trade: Jul 22nd, 5:29 PM EDT
Via Benzinga · July 18, 2025
Via Benzinga · July 11, 2025
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.
Via Benzinga · July 11, 2025

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · February 7, 2025

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Via Stocktwits · January 30, 2025

Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Via Benzinga · January 30, 2025

Via Benzinga · January 30, 2025

Via Benzinga · January 30, 2025

Via Benzinga · November 29, 2024

Via Benzinga · May 27, 2024

Via Benzinga · May 10, 2024

Via Benzinga · April 24, 2024

Via Benzinga · April 23, 2024

Via Benzinga · April 15, 2024

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Via Benzinga · April 15, 2024

Via Benzinga · April 15, 2024

Via Benzinga · February 6, 2024

Via Benzinga · January 15, 2024

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via Benzinga · December 5, 2023